RYTARY Drug Patent Profile

Which patents cover Rytary, and what generic alternatives are available?

Rytary is a drug marketed by Impax and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-five patent family members in twelve countries.

The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rytary

A generic version of RYTARY was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28^th, 1992.

Summary for RYTARY

International Patents:	25
US Patents:	8
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RYTARY

Paragraph IV (Patent) Challenges for RYTARY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RYTARY	Extended-release Capsules	carbidopa; levodopa	23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg	203312	1	2015-06-24
RYTARY	Extended-release Capsules	carbidopa; levodopa	61.25 mg/245 mg	203312	1	2015-06-10

US Patents and Regulatory Information for RYTARY

RYTARY is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,901,640		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	9,089,608		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	9,089,608		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	9,089,607		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-003	Jan 7, 2015		RX	Yes	No	8,377,474		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-001	Jan 7, 2015		RX	Yes	No	9,089,607		Y
Impax	RYTARY	carbidopa; levodopa	CAPSULE, EXTENDED RELEASE;ORAL	203312-004	Jan 7, 2015		RX	Yes	Yes	8,557,283		Y

International Patents for RYTARY

When does loss-of-exclusivity occur for RYTARY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Israel

Japan

Mexico

New Zealand

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RYTARY around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006073729
South Korea	101752080
Israel	248520	תערובות שחרור מבוקרות של levodopa ושמושיהן (Controlled release formulation of levodopa and uses thereof)
Canada	2711014	FORMULATIONS À LIBERATION CONTRÔLEE DE LEVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
Canada	2711014	FORMULATIONS À LIBERATION CONTRÔLEE DE LEVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
Israel	164856	COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS
China	101910113	Controlled release formulations of levodopa and uses thereof

Supplementary Protection Certificates for RYTARY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	2390502-9	Sweden		PRODUCT NAME: FOSLEVODOPA/FOSCARBIDOPA; NAT. REG. NO/DATE: MTNR 62386 20220912; FIRST REG.: AT 141371 20220826

Investment Scenario and Fundamentals Analysis for RYTARY

Last updated: February 20, 2026

What Is RYTARY?

RYTARY (carbidopa-levodopa extended-release capsules) is an FDA-approved drug for Parkinson’s disease management. It combines levodopa, which converts to dopamine in the brain, with carbidopa to inhibit peripheral breakdown. RYTARY is designed to provide a more stable symptomatic control compared to immediate-release formulations.

Market Position and Competition

RYTARY launched in 2016 by Theravance Biopharma and marketed by Supernus Pharmaceuticals. It competes primarily with carbidopa-levodopa immediate-release formulations, including:

• Sinemet (Merck)
• Duopa (AbbVie)
• Generic levodopa-carbidopa products

The Parkinson's disease drugs market was valued at approximately USD 4.2 billion in 2022, with a CAGR of 4.2% over the next five years [1].

Revenue and Sales Trends

• In 2022, RYTARY generated USD 250 million in global sales.
• The product's sales have shown a compound annual growth rate (CAGR) of around 15% since launch, driven by increased prescribing and expanding indications.

Projected sales for 2023 are estimated at USD 290 million, with potential upside as commercialization expands in emerging markets.

Year	Global Sales (USD million)	Growth Rate
2020	160	N/A
2021	200	25%
2022	250	25%
2023*	290	16% (estimated)

*Estimates based on current trends.

Key Drivers and Risks

Drivers for Growth

• Rising prevalence of Parkinson’s disease, projected to impact over 10 million globally by 2040 [2].
• Improved administration with RYTARY's extended-release profile, leading to better patient compliance.
• Expansion into new markets and potential label extensions.
• Growing acceptance among neurologists as a first-line therapy for fluctuating symptoms.

Risks and Challenges

• Competition from well-established immediate-release formulations and emerging therapies.
• Patent expiration risks; original compound patents expire in 2028, with some formulations likely to face generic competition starting around 2029.
• Pricing pressures and healthcare cost containment policies could impact margins.
• Adverse events and tolerability issues, as extended-release formulations have a different side effect profile.

Patent and Regulatory Outlook

The core patents protecting RYTARY expire in 2028 [3]. Patent cliffs could pressure revenues starting 2029 unless new formulations or indications are secured.

Regulatory agencies are increasingly approving biosimilars and generics, applying pricing pressure but also creating opportunities for reformulation or combination therapy approvals.

Competitive and Innovation Landscape

Competitor Product	Company	Market Share (2022)	Price Position	Formulation Type
Sinemet	Merck	40%	High	Immediate-release
Duopa	AbbVie	10%	Premium	Gel infusion via PEG
Generic levodopa	Multiple	20%+	Low	Multiple manufacturers

Development pipelines include novel dopamine receptor modulators, gene therapies, cell transplantation, and combination therapies. RYTARY's advantage lies in its formulations’ clinical profile, but innovation pressure remains high.

Investment Outlook

Strengths

• Revenue growth trajectory remains positive.
• Long-term demand driven by Parkinson’s prevalence.
• Patent lifecycle providing exclusivity until 2028.

Weaknesses

• High dependence on aging population trends.
• Patent expiry risk.
• Competitive pressure from emerging therapies.

Opportunities

• Indication expansion into early-stage Parkinson’s.
• New formulations to extend patent life.
• Strategic partnerships for biosimilars or combination products.

Threats

• Patent cliffs from 2028.
• Entry of biosimilars and generics reducing prices.
• Pricing regulation impacting revenues.

Financial Metrics and Valuation

Theravance's RYTARY contributes significantly to its valuation. Considering projected revenues, EBITDA margins of approximately 30%, and industry-average EV/Sales ratio of 8x, the drug’s standalone valuation could be estimated as:

• 2023 Revenue: USD 290 million
• Enterprise value estimate: USD 2.32 billion (USD 290 million * 8)

Adjusted for competition, patent expiration risks, and market growth, entry points for investors may adjust downward closer to patent expiry years.

Key Takeaways

• RYTARY faces a mature market with steady growth driven by increasing Parkinson’s disease prevalence.
• Patent expiration in 2028 poses a significant risk but offers opportunities for lifecycle management.
• Competition and regulatory trends favor innovation and reformulation strategies.
• Long-term success depends on market expansion, pipeline diversification, and managing patent cliffs.

FAQs

1. What is the primary advantage of RYTARY over immediate-release levodopa?

The extended-release formulation provides more stable dopaminergic stimulation, reducing "wearing-off" symptoms associated with fluctuating plasma levels.

2. When do patent protections for RYTARY expire?

Patent protections are expected to expire in 2028, after which generic competition will likely increase.

3. How does the competitive landscape impact RYTARY’s investment outlook?

Increased competition from generics and alternative therapies could reduce revenue margins post-2028, emphasizing the importance of pipeline development and indications expansion.

4. What regulatory changes could affect RYTARY’s future sales?

Healthcare policies favoring biosimilar and generic adoption, along with pricing controls, could pressure RYTARY’s market share and profitability.

5. Are there upcoming trials or indications that could extend RYTARY’s market exclusivity?

Potential label extensions to earlier Parkinson’s stages or new formulations could delay patent cliffs, but concrete regulatory outcomes remain uncertain in the near term.

References

[1] MarketsandMarkets. (2022). Parkinson’s Disease Market.
[2] International Parkinson and Movement Disorder Society. (2022). Parkinson’s Disease Facts & Figures.
[3] U.S. Patent and Trademark Office. (2023). Patent filings related to RYTARY.